Drug Profile
Seladelpar - CymaBay Therapeutics
Alternative Names: MBX 8025; RWJ 800025Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Ortho-McNeil
- Developer CymaBay Therapeutics
- Class Acetates; Anti-inflammatories; Antifibrotics; Antihyperlipidaemics; Hepatoprotectants; Small molecules
- Mechanism of Action C-reactive protein inhibitors; Peroxisome proliferator-activated receptor delta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Primary biliary cirrhosis
- Phase II Hyperlipidaemia; Hyperlipoproteinaemia type IIa; Primary sclerosing cholangitis
- Phase I Liver disorders
- Discontinued Non-alcoholic steatohepatitis